Business Wire (Thu, 8:01AM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,467 people get STJ articles and Market Currents by email alert.
Get email alerts on STJ »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
Business Wire (May 8, 2013)
-
-
Business Wire (May 3, 2013)
-
Business Wire (May 2, 2013)
-
Business Wire (May 1, 2013)
-
Business Wire (Apr 30, 2013)
-
-
Business Wire (Apr 17, 2013)
-
Business Wire (Apr 4, 2013)
-
5 Cheap Dividend Stocks Worth InvestigatingMarshall Hargrave • Tue, Mar 26 -
Business Wire (Mar 21, 2013)
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
Boston Scientific Could Benefit From St. Jude Medical's TroublesTrefis • Tue, Nov 27, 2012 -
-
-
Why St. Jude Is Poised To Become A Solid Income StockValuentum • Thu, Sep 20, 2012 -
St. Jude Medical's Weaker Guidance Presents Another OpportunityStephen Simpson • Wed, Jul 18, 2012
-
-
-
-
-
-
St. Jude Medical: Earnings PreviewZacks Investment Research • Wed, Jan 25, 2012
-
Quality, With A Dividend, Now On Sale: St. Jude MedicalK202 • Tue, Jan 10, 2012 -
St. Jude Remains On Our Dividend Growth Watch ListValuentum • Wed, Jan 4, 2012
-
-
St. Jude: Earnings PreviewZacks Investment Research • Wed, Oct 19, 2011
-
-
-
-
5 Cheap Dividend Stocks Worth InvestigatingMarshall Hargrave • Tue, Mar 26
-
-
-
-
-
-
Fortune Could Favor A Bolder TerumoStephen Simpson • Thu, Feb 21
-
-
-
-
-
-
-
-
Checking The Pulse Of Healthcare StocksStock Traders Daily • Tue, Jan 22
-
-
-
St. Jude Medical Inc. - Analyst/Investor DayFri, Feb 3, 2012
-
St. Jude Medical Q2 2010 Earnings Call TranscriptThu, Jul 22, 2010
-
St. Jude Medical Inc. Q1 2010 Earnings Call TranscriptWed, Apr 21, 2010
-
St. Jude Medical Inc. Q4 2009 Earnings Call TranscriptWed, Jan 27, 2010
-
St. Jude Medical Inc., Q3 2009 Earnings Call TranscriptWed, Oct 21, 2009
-
St. Jude Medical, Inc. Q2 2009 Earnings Call TranscriptWed, Jul 22, 2009
-
St. Jude Medical, Inc. Q1 2009 Earnings Call TranscriptWed, Apr 22, 2009 • 1 Comment
-
St. Jude Medical Inc. Q4 2008 Earnings Call TranscriptTue, Jan 27, 2009
-
Business Wire (May 8, 2013)
-
Business Wire (May 3, 2013)
-
Business Wire (May 2, 2013)
-
Business Wire (May 1, 2013)
-
Business Wire (Apr 30, 2013)
-
Business Wire (Apr 17, 2013)
-
at CNBC.com (Apr 14, 2013)
-
at CNBC.com (Apr 9, 2013)
-
Business Wire (Apr 4, 2013)
-
Business Wire (Mar 21, 2013)
-
Business Wire (Mar 20, 2013)
-
Business Wire (Mar 11, 2013)
-
Business Wire (Feb 27, 2013)
-
at Fox Business (Feb 25, 2013)
STJ vs. ETF Alternatives
Company Description
St. Jude Medical, Inc. develops, manufactures and distributes cardiovascular medical devices for the global cardiac rhythm management, cardiology and cardiac surgery and atrial fibrillation therapy areas and neurostimulation medical devices for the management of chronic pain. Our four operating... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, May 2, 2:56 PM St. Jude Medical, Inc. (STJ) declares $0.25/share quarterly dividend, in line with previous. Forward yield 2.46%. For shareholders of record June 28. Payable July 31. Ex-div date June 26. (PR) Comment! [Dividends]
- Wednesday, April 17, 5:50 PM Volcano (VOLC) files a lawsuit against St. Jude Medical (STJ) for patent infringement, accusing STJ of violating its patent on certain guide wire methods used in its devices. The suit is just another salvo in an ongoing patent war between the two companies over pressure wire technology used their heart devices. The war actually began nearly three years ago, when STJ filed suit against VOLC for infringement of 5 of its own patents for pressure guide wire products. Comment! [Healthcare]
- Wednesday, April 17, 8:20 AM From St. Jude's (STJ) earnings call. Lowers 2013 sales guidance to $5.36-5.48B, representing a cut of $107M at the midpoint. Analysts expect $5.7B. The lower forecast is due to changes in currency assumptions and a more cautious outlook in its cardiovascular business. Expects currency neutral sales growth of -1% to +2%. (Q1 earnings) Comment! [Earnings, Breaking News, Healthcare]
- Wednesday, April 17, 8:10 AM More on St. Jude Medical (STJ) Q1: net profit +5% to $223M, with the company enjoying a $21M tax benefit but taking $61M in charges, primarily related to restructuring and acquisition activities. Forex fluctuations hurt sales by $17M. Sales breakdown: Cardiac Rhythm Management -8% to $678M; Atrial Fibrillation +5% to $233M; total cardiovascular sales -2% to $328M. Expects Q2 EPS of $0.93-$0.95 vs consensus of 0.94 and FY EPS of $3.68-$3.73 vs $3.95. (PR) Comment! [Earnings]
- Wednesday, April 17, 7:31 AM St. Jude Medical (STJ): Q1 EPS of $0.92 beats by $0.01. Revenue of $1.34B (-4% Y/Y) misses by $0.02B. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Wednesday, April 17, 12:05 AM Notable earnings before Wednesday’s open: ABT, ASML, BAC, BK, DGX, DOV, FCFS, HBAN, MAT, PNC, STJ, TXT Comment! [Earnings]
- Tuesday, April 16, 5:30 PM Notable earnings before Wednesday’s open: ABT, ASML, BAC, BK, DGX, DOV, FCFS, HBAN, MAT, PNC, STJ, TXT Comment! [Earnings]
- Friday, April 5, 5:00 AM St. Jude Medical (STJ) has been hit with lawsuits in California that allege that defects with the manufacturing and oversight of its now recalled Riata heart defibrillator "leads" injured or killed over 30 patients. The suits could have a wider impact, as they seek to get round a 2008 Supreme Court ruling that protected medical-device companies from product-liability claims as long as they complied with FDA standards. Comment! [Healthcare]
- Friday, March 8, 2:55 PM St. Jude Medical (STJ +1.1%) is up today after the company reports the first patient implant in a new trial evaluating the company's Aplatzer Cardiac Plug, a device for the prevention of stroke. The trial is designed to determine if the device is safe and effective in preventing thrombus from migrating out of the left atrial appendage in patients with non-valvular atrial fibrillation who have a high risk for stroke. Comment! [Healthcare, On the Move]
- Monday, February 25, 8:57 AM St. Jude Medical, Inc. (STJ) declares $0.25/share quarterly dividend, 9% increase from prior dividend of $0.23. Forward yield 2.43%. For shareholders of record Mar. 29. Payable Apr. 30. Ex-div date Mar. 27. (PR) Comment! [Dividends]
- Friday, February 15, 2:10 PM St. Jude Medical (STJ -3.4%) has been working overtime to convince the Street that its Durata heart device leads are safe, but Cowen doesn't take the bait, downgrading the stock to Market Underperform over concerns that the new heart wire is no different from the ones already taken off the market. The firm cites a "significant risk" of a recall, which would " meaningfully damage" its defibrillator and pacemaker business. Comment! [Healthcare, On the Move]
-
Wednesday, February 13, 9:42 AM
St. Jude Medical (STJ +0.5%) has issued a voluntary Class 1 recall of its Amplatzer TorqVue FX Delivery System, which is used for hole in the heart surgery, after the company discovered that the device could fracture in a number of cases, causing serious damage and even death. However, no serious injuries have occurred.
Comment! [Healthcare] - Wednesday, January 23, 9:04 AM More on St. Jude Medical (STJ +0.8%) Q4: net profit -4% to $120M despite cutting SG&A costs by 18% and R&D spending by 11%. Cardiac rhythm management sales -6% to $682M, atrial fibrillation products +10% to $239M, total cardiovascular sales flat at $338M. Expects Q1 EPS of $0.91-0.93 vs consensus of $0.89 and 2013 EPS of $3.68-3.73 vs $3.62. Comment! [Earnings, Healthcare]
- Wednesday, January 23, 7:32 AM St. Jude Medical (STJ): Q4 EPS of $0.92 beats by $0.03. Revenue of $1.37B (-2% Y/Y) in-line. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Wednesday, January 23, 12:05 AM Notable earnings before Wednesday’s open: ABBV, ABT, APD, ATI, BHI, CHKP, COH, DGX, FNFG, GD, LCC, MCD, MSI, NVS, PX, RES, SAP, STJ, TEL, TXT, UTX, WLP Comment! [Earnings]
- Tuesday, January 22, 5:30 PM Notable earnings before Wednesday’s open: ABBV, ABT, APD, ATI, BHI, CHKP, COH, DGX, FNFG, GD, LCC, MCD, MSI, NVS, PX, RES, SAP, STJ, TEL, TXT, UTX, WLP Comment! [Earnings]
-
Alan Brochstein
$STJ has had a nice run, but it's still a bit cheap to the peers despite better growth potential - View all 0 replies
-
Alan Brochstein
$STJ reacted well to an independent report that its Durata leads don't have the alleged problems that some suggest - stock is cheap at 12 PE - View all 1 replies
-
WallStreetDebunker: There are many stocks in the medical devices sector with low valuations and good demographic trends ahead. Definitely good hunting grounds.
-
- View all 0 replies
-
Alan Brochstein
$EW pounded on miss and lower guidance - not bad at 70, could be a buy at 68 (but I prefer $STJ) - View all 0 replies
-
Alan Brochstein
$STJ sales reduction mainly due to stronger dollar but distributed products in Japan are under pressure too - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 5 replies
-
-
Alan Brochstein: $RMD is good stuff - it's on my watchlist and one of my clients owns a lot. At this point, it's a hold
-
Alan Brochstein
$STJ had a nice outlook - conservative yet delivering EPS above expectations. Raising my target to 60 - View all 0 replies
LATEST REPLIES
-
Alan Brochstein
$STJ reacted well to an independent report that its Durata leads don't have the alleged problems that some suggest - stock is cheap at 12 PE - View all 1 replies
-
WallStreetDebunker: There are many stocks in the medical devices sector with low valuations and good demographic trends ahead. Definitely good hunting grounds.
-
- View all 5 replies
-
-
Alan Brochstein: $RMD is good stuff - it's on my watchlist and one of my clients owns a lot. At this point, it's a hold
-
- View all 1 replies
-
-
- View all 8 replies
-
-
Jeremy Johnson: STJ is not expensive, but it is getting close to fair value. Fair value stocks are still good to own... fair equity return is 8% a year.
-
Dividend Sheet
Best Healthcare Stock Picks For 2012: http://bit.ly/w32xHl + $MRK $NVS $STJ $TEVA $TMO $CELG $GILD - View all 2 replies
-
-
-
- View all 1 replies
-
-
- View all 1 replies
-
-
- View all 1 replies
-
jason2788: go denver is right, i skipped around my house like a little school girl.
-
Alan Brochstein
Lots of pain in med devices - STJ and ZMH stand out to me for near-term reversal potential - View all 3 replies
-
Alan Brochstein: The CardioMEMS panel ruling has an immaterial impact on near-term financials, though it is disappointing.
-
Ocean Man: Minor bad news that hits harder than it should = stocks on sale.
-
fmhaynes11
Did STJ deserve the hit caused by FDA ruling on CardioMEMS heart implant device ? Is STJ that reliant on that technology ? - View all 1 replies
-